200 Families Battle Alzheimer's to Help Future Generations

June Ward knows Alzheimer's will likely claim her mind within years, but she's not fighting just for herself. The 64-year-old carries a rare gene mutation that virtually guarantees she'll develop the disease, yet she volunteers for research studies knowing the treatments may come too late for her.

"It's not for us," Ward says. "It's for my sister's children and their children, so that they won't have the same 'nothing' to choose from."

Ward belongs to the Dominantly Inherited Alzheimer Network, or DIAN, a remarkable group of over 200 families across 18 countries. These families carry mutations that cause Alzheimer's symptoms to appear in middle age or earlier, making them invaluable to researchers who can predict not just if, but when the disease will strike.

For two decades, these families have opened their lives to science. They've endured brain scans, lumbar punctures, and experimental drug trials, helping researchers unlock crucial mysteries about how Alzheimer's begins and progresses.

Their sacrifice has paid off in real breakthroughs. Brain scans of DIAN participants revealed that Alzheimer's changes begin 20 years before memory loss appears, transforming how scientists understand the disease. The network's clinical trials showed certain drugs could reduce harmful amyloid plaques in the brain.

Studies published in 2025 suggested that targeting amyloid very early might delay symptoms in people with mutations. By testing experimental treatments, DIAN families helped pave the way for lecanemab and donanemab, the two amyloid drugs now available to patients.

The Ripple Effect

The impact of these families extends far beyond their own communities. Every brain scan, every blood test, every clinical trial adds crucial data that helps millions of Alzheimer's patients worldwide who don't carry these rare mutations.

DIAN researchers have even discovered rare individuals who inherit the mutation but somehow never develop Alzheimer's. Understanding their protection could unlock treatments for everyone at high risk.

Some participants have turned their family's diagnosis into a calling. Lindsay, who watched her father develop Alzheimer's at 48, immersed herself in brain science and joined DIAN at 18, enduring uncomfortable tests to advance research.

The network, run by WashU Medicine in St. Louis, now faces an uncertain future. Federal funding cuts and delays have forced DIAN to maintain only essential functions while awaiting critical grants from the National Institutes of Health.

Dr. Tammie Benzinger, who oversees brain imaging for DIAN, warns that without funding, "the network that's been built up, the years that have gone into the training and the relationships—all of that would fall apart."

These families have given science two decades of hope, and their work continues to light the path toward better treatments for everyone.